No, but the Medicines and Healthcare products Regulatory Agency did have discussions on the underlying data in this area with officials responsible for the medical dictionary for regulatory activities, which resulted in them adding the lower level term “post-SSRI sexual dysfunction” to the regulatory dictionary under sexual dysfunction.

Since the introduction of the severity modifier, the National Institute for Health and Care Excellence (NICE) has approved 34 out of 35 blood cancer medicines it evaluated, reflecting an approval rate of 97%. Of these topics, a severity weighting was applied in nine topics.

Chimeric antigen receptor T-cell (CAR-T) is a type of personalised immunotherapy in which a patient's own T-cells are harvested, genetically modified, and then reintroduced into the body so that they can detect and destroy cancer cells. England was the first country in Europe to deliver CAR-T. It has been available in selected specialist centres in the National Health Service in England since 2018.

As an innovative treatment option, NHS England has supported the development and subsequent refinement of a CAR-T specific tariff, working with NHS clinical and costing experts to ensure that CAR-T centres receive the funding they need to deliver these complex treatments safely and effectively. This work has informed the advice provided by the NHS to NICE.

Since the introduction of the severity modifier, the National Institute for Health and Care Excellence (NICE) has approved 34 out of 35 blood cancer medicines it evaluated, reflecting an approval rate of 97%. Of these topics, a severity weighting was applied in nine topics.

Chimeric antigen receptor T-cell (CAR-T) is a type of personalised immunotherapy in which a patient's own T-cells are harvested, genetically modified, and then reintroduced into the body so that they can detect and destroy cancer cells. England was the first country in Europe to deliver CAR-T. It has been available in selected specialist centres in the National Health Service in England since 2018.

As an innovative treatment option, NHS England has supported the development and subsequent refinement of a CAR-T specific tariff, working with NHS clinical and costing experts to ensure that CAR-T centres receive the funding they need to deliver these complex treatments safely and effectively. This work has informed the advice provided by the NHS to NICE.

Since the introduction of the severity modifier, the National Institute for Health and Care Excellence (NICE) has approved 34 out of 35 blood cancer medicines it evaluated, reflecting an approval rate of 97%. Of these topics, a severity weighting was applied in nine topics.

Chimeric antigen receptor T-cell (CAR-T) is a type of personalised immunotherapy in which a patient's own T-cells are harvested, genetically modified, and then reintroduced into the body so that they can detect and destroy cancer cells. England was the first country in Europe to deliver CAR-T. It has been available in selected specialist centres in the National Health Service in England since 2018.

As an innovative treatment option, NHS England has supported the development and subsequent refinement of a CAR-T specific tariff, working with NHS clinical and costing experts to ensure that CAR-T centres receive the funding they need to deliver these complex treatments safely and effectively. This work has informed the advice provided by the NHS to NICE.

Further to the answer provided on 28 September in response to question HL3452, since 1 January 2025, fulfilment of private prescriptions for puberty blockers for people under 18 years old with gender incongruence or gender dysphoria has been banned under the provisions of section 62 of the Medicines Act 1968. This includes prescriptions issued by prescribers in the European Economic Area (EEA) or Switzerland.

While United Kingdom pharmacies can otherwise dispense prescriptions issued by appropriately regulated prescribers in the EEA or Switzerland, they can refuse to dispense a prescription if they have concerns about whether it is genuine, clinically appropriate, or safe. The Government is currently considering the findings of our recent call for evidence on non-National Health Service prescribing, including on the recognition of EEA and Swiss prescriptions in the UK.

The regulatory oversight of clinics operating outside the England, and not providing regulated activities in England, is a matter for the governments in the jurisdiction in which those clinics are based.

The General Medical Council is clear that a decision about whether to enter into a shared care agreement is for the general practitioner (GP) to make. NHS England has provided specific guidance advising GPs against shared care agreements with unregulated providers in relation to hormone medication to children and young people under 18 years old as a response to gender incongruence or gender dysphoria.

Further to the answer provided on 28 September in response to question HL3452, since 1 January 2025, fulfilment of private prescriptions for puberty blockers for people under 18 years old with gender incongruence or gender dysphoria has been banned under the provisions of section 62 of the Medicines Act 1968. This includes prescriptions issued by prescribers in the European Economic Area (EEA) or Switzerland.

While United Kingdom pharmacies can otherwise dispense prescriptions issued by appropriately regulated prescribers in the EEA or Switzerland, they can refuse to dispense a prescription if they have concerns about whether it is genuine, clinically appropriate, or safe. The Government is currently considering the findings of our recent call for evidence on non-National Health Service prescribing, including on the recognition of EEA and Swiss prescriptions in the UK.

The regulatory oversight of clinics operating outside the England, and not providing regulated activities in England, is a matter for the governments in the jurisdiction in which those clinics are based.

The General Medical Council is clear that a decision about whether to enter into a shared care agreement is for the general practitioner (GP) to make. NHS England has provided specific guidance advising GPs against shared care agreements with unregulated providers in relation to hormone medication to children and young people under 18 years old as a response to gender incongruence or gender dysphoria.

Further to the answer provided on 28 September in response to question HL3452, since 1 January 2025, fulfilment of private prescriptions for puberty blockers for people under 18 years old with gender incongruence or gender dysphoria has been banned under the provisions of section 62 of the Medicines Act 1968. This includes prescriptions issued by prescribers in the European Economic Area (EEA) or Switzerland.

While United Kingdom pharmacies can otherwise dispense prescriptions issued by appropriately regulated prescribers in the EEA or Switzerland, they can refuse to dispense a prescription if they have concerns about whether it is genuine, clinically appropriate, or safe. The Government is currently considering the findings of our recent call for evidence on non-National Health Service prescribing, including on the recognition of EEA and Swiss prescriptions in the UK.

The regulatory oversight of clinics operating outside the England, and not providing regulated activities in England, is a matter for the governments in the jurisdiction in which those clinics are based.

The General Medical Council is clear that a decision about whether to enter into a shared care agreement is for the general practitioner (GP) to make. NHS England has provided specific guidance advising GPs against shared care agreements with unregulated providers in relation to hormone medication to children and young people under 18 years old as a response to gender incongruence or gender dysphoria.

Further to the answer provided on 28 September in response to question HL3452, since 1 January 2025, fulfilment of private prescriptions for puberty blockers for people under 18 years old with gender incongruence or gender dysphoria has been banned under the provisions of section 62 of the Medicines Act 1968. This includes prescriptions issued by prescribers in the European Economic Area (EEA) or Switzerland.

While United Kingdom pharmacies can otherwise dispense prescriptions issued by appropriately regulated prescribers in the EEA or Switzerland, they can refuse to dispense a prescription if they have concerns about whether it is genuine, clinically appropriate, or safe. The Government is currently considering the findings of our recent call for evidence on non-National Health Service prescribing, including on the recognition of EEA and Swiss prescriptions in the UK.

The regulatory oversight of clinics operating outside the England, and not providing regulated activities in England, is a matter for the governments in the jurisdiction in which those clinics are based.

The General Medical Council is clear that a decision about whether to enter into a shared care agreement is for the general practitioner (GP) to make. NHS England has provided specific guidance advising GPs against shared care agreements with unregulated providers in relation to hormone medication to children and young people under 18 years old as a response to gender incongruence or gender dysphoria.

Further to the answer provided on 28 September in response to question HL3452, since 1 January 2025, fulfilment of private prescriptions for puberty blockers for people under 18 years old with gender incongruence or gender dysphoria has been banned under the provisions of section 62 of the Medicines Act 1968. This includes prescriptions issued by prescribers in the European Economic Area (EEA) or Switzerland.

While United Kingdom pharmacies can otherwise dispense prescriptions issued by appropriately regulated prescribers in the EEA or Switzerland, they can refuse to dispense a prescription if they have concerns about whether it is genuine, clinically appropriate, or safe. The Government is currently considering the findings of our recent call for evidence on non-National Health Service prescribing, including on the recognition of EEA and Swiss prescriptions in the UK.

The regulatory oversight of clinics operating outside the England, and not providing regulated activities in England, is a matter for the governments in the jurisdiction in which those clinics are based.

The General Medical Council is clear that a decision about whether to enter into a shared care agreement is for the general practitioner (GP) to make. NHS England has provided specific guidance advising GPs against shared care agreements with unregulated providers in relation to hormone medication to children and young people under 18 years old as a response to gender incongruence or gender dysphoria.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

The NHS Health Check programme was introduced in England in April 2009. It has been subject to a number of subsequent evaluations and reviews, the latest of which was published in 2021.

The programme currently engages over 1.3 million people each year and, through behavioural and clinical interventions, prevents approximately 500 heart attacks and strokes a year. The NHS Health Check also identifies over 333,000 cases of obesity, 340,000 cases of high blood pressure, and 900,000 cases of raised cholesterol each year.

We are refreshing the NHS Health Check’s Best Practice Guidance with practical examples and tips to help commissioners and providers to improve delivery and support uptake of the programme. We are also developing the NHS Health Check Online which will allow people to undertake their NHS Health Check at home, at a time and place convenient to them.

As announced in the recently published Cardiovascular Disease Modern Service Framework, we have commissioned the National Institute for Health and Care Research to conduct an evidence review on the scope of the programme, which includes an update to the modelling assumptions used to estimate its impact.

The evidence review is expected to be completed by the second half of 2027, and we will consider the findings as appropriate to inform future policy development.

We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.

No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.

The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.

We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.

No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.

The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.

We have established a programme that will, alongside closer working and a safe transfer checklist, help to ensure that integrated care boards (ICBs) are ready to take on their new responsibilities for vaccination from April 2027. We will also ensure there is appropriate accountability for vaccination services after the responsibility for their commissioning is delegated to ICBs. Work is ongoing and aligned to the merger of the Department of Health and Social Care and NHS England.

No changes in the current reporting frameworks in this area are planned, but we keep all such matters under regular review.

The Department does not collect data on the costs of responding to outbreaks of vaccine-preventable infectious disease, but the methodology for assessing the cost-effectiveness of vaccination programmes routinely accounts for benefits such as avoided National Health Service and social care costs, as well as improved health outcomes.

Improving care for people with migraine, including those whose symptoms are associated with menopause, is supported through a range of National Health Service initiatives. National Institute for Health and Care Excellence guidance provides evidence-based recommendations on the diagnosis and management of migraine, while NHS England supports improvements in headache and migraine services through initiatives such as the NHS RightCare Headache and Migraine Toolkit, which aims to improve pathways between primary and specialist care and ensure patients receive the right intervention at the earliest opportunity.

NHS England announced on 10 September that migraine would be added to the list of conditions for which individuals can get further support from participating prescribing pharmacies under the Pharmacy First programme, later this autumn. While migraine affects a higher proportion of women than men, the services referred to above are available to both men and women in need of support.

Improving care for people with migraine, including those whose symptoms are associated with menopause, is supported through a range of National Health Service initiatives. National Institute for Health and Care Excellence guidance provides evidence-based recommendations on the diagnosis and management of migraine, while NHS England supports improvements in headache and migraine services through initiatives such as the NHS RightCare Headache and Migraine Toolkit, which aims to improve pathways between primary and specialist care and ensure patients receive the right intervention at the earliest opportunity.

NHS England announced on 10 September that migraine would be added to the list of conditions for which individuals can get further support from participating prescribing pharmacies under the Pharmacy First programme, later this autumn. While migraine affects a higher proportion of women than men, the services referred to above are available to both men and women in need of support.